Symbols / QNRX Stock $6.21 -4.17% Quoin Pharmaceuticals, Ltd.

Healthcare • Biotechnology • United States • NCM
QNRX (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index —
Sector Healthcare
Industry Biotechnology
CEO —
Exch · Country NCM · United States
Market Cap 11.20M
Enterprise Value —
Income —
Sales —
FCF (ttm) -7.96M
Book/sh —
Cash/sh —
Employees —
Insider 10d —
IPO —
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout —
P/E —
Forward P/E —
PEG —
P/S —
P/B —
P/C —
EV/EBITDA —
EV/Sales —
Quick Ratio —
Current Ratio —
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -14.80
EPS next Y —
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) —
Earnings (prior) —
ROA —
ROE —
ROIC —
Gross Margin —
Oper. Margin —
Profit Margin —
Shs Outstand 1.80M
Shs Float —
Insider Own —
Instit Own —
Short Float —
Short Ratio —
Short Interest —
52W High —
vs 52W High —
52W Low —
vs 52W Low —
Beta —
Impl. Vol. —
Rel Volume —
Avg Volume —
Volume —
Target (mean) $29.67
Tgt Median $35.00
Tgt Low $14.00
Tgt High $40.00
# Analysts —
Recom —
Prev Close $6.48
Price $6.21
Change -4.17%
About

Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrome and ichthyosis. It also develops QRX008 for the treatment of scleroderma, which is in pre-clinical stage; and QRX009, to treat microcystic lymphatic malformations, venous malformations, angiofibroma, and other diseases. It has a research agreement with Queensland University of Technology. Quoin Pharmaceuticals, Ltd. was founded in 2018 and is based in Ashburn, Virginia. Quoin Pharmaceuticals, Ltd. is a subsidiary of Skinvisible, Inc.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$29.67
Mean price target
2. Current target
$6.21
Latest analyst target
3. DCF / Fair value
$-79.45
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$6.21
Low
$14.00
High
$40.00
Mean
$29.67

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2024-03-15 main Maxim Group Buy → Buy $4
News
RSS: Latest QNRX news
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
16.29
+70.97%
9.53
+1.60%
9.38
+1.30%
9.26
Research And Development
9.80
+172.10%
3.60
+8.91%
3.31
+23.76%
2.67
Selling General And Administration
6.49
+9.49%
5.93
-2.38%
6.07
-7.81%
6.58
General And Administrative Expense
6.49
+9.49%
5.93
-2.38%
6.07
-7.81%
6.58
Other Gand A
6.49
+9.49%
5.93
-2.38%
6.07
-7.81%
6.58
Total Expenses
16.29
+70.97%
9.53
+1.60%
9.38
+1.30%
9.26
Operating Income
-16.29
-70.97%
-9.53
-1.60%
-9.38
-1.30%
-9.26
EBITDA
-16.19
-71.72%
-9.43
-1.66%
-9.27
-8.31%
-8.56
Normalized EBITDA
-16.19
-71.63%
-9.44
-1.77%
-9.27
-3.25%
-8.98
Reconciled Depreciation
0.10
+0.00%
0.10
-3.57%
0.10
-0.32%
0.10
EBIT
-16.29
-70.97%
-9.53
-1.60%
-9.38
-8.20%
-8.67
Total Unusual Items
0.00
-46.95%
0.01
+379.61%
-0.00
-100.64%
0.42
Total Unusual Items Excluding Goodwill
0.00
-46.95%
0.01
+379.61%
-0.00
-100.64%
0.42
Special Income Charges
—
—
0.00
-100.00%
0.42
Other Special Charges
—
—
—
-0.42
Net Income
-15.80
-76.34%
-8.96
-3.18%
-8.69
+7.41%
-9.38
Pretax Income
-15.80
-76.34%
-8.96
-3.18%
-8.69
+7.41%
-9.38
Net Non Operating Interest Income Expense
0.48
-13.68%
0.56
-19.60%
0.69
+212.34%
-0.62
Interest Expense Non Operating
—
—
0.00
-100.00%
0.71
Net Interest Income
0.48
-13.68%
0.56
-19.60%
0.69
+212.34%
-0.62
Interest Expense
—
—
0.00
-100.00%
0.71
Interest Income Non Operating
0.48
-13.68%
0.56
-19.60%
0.69
+625.48%
0.10
Interest Income
0.48
-13.68%
0.56
-19.60%
0.69
+625.48%
0.10
Other Income Expense
0.00
-46.95%
0.01
+379.61%
-0.00
-100.54%
0.49
Other Non Operating Income Expenses
—
—
—
0.08
Gain On Sale Of Security
0.00
-46.95%
0.01
+379.61%
-0.00
-305.28%
0.00
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-15.80
-76.34%
-8.96
-3.18%
-8.69
+7.41%
-9.38
Net Income From Continuing Operation Net Minority Interest
-15.80
-76.34%
-8.96
-3.18%
-8.69
+7.41%
-9.38
Net Income From Continuing And Discontinued Operation
-15.80
-76.34%
-8.96
-3.18%
-8.69
+7.41%
-9.38
Net Income Continuous Operations
-15.80
-76.34%
-8.96
-3.18%
-8.69
+7.41%
-9.38
Normalized Income
-15.81
-76.24%
-8.97
-3.29%
-8.68
+11.38%
-9.80
Net Income Common Stockholders
-15.80
-76.34%
-8.96
-3.18%
-8.69
+8.05%
-9.45
Otherunder Preferred Stock Dividend
—
—
0.00
-100.00%
0.07
Diluted EPS
—
-66.85
+80.19%
-337.47
+79.40%
-1,638.23
Basic EPS
—
-66.85
+80.19%
-337.47
+79.40%
-1,638.23
Basic Average Shares
—
0.13
+420.43%
0.03
+346.43%
0.01
Diluted Average Shares
—
0.13
+420.43%
0.03
+346.43%
0.01
Diluted NI Availto Com Stockholders
-15.80
-76.34%
-8.96
-3.18%
-8.69
+8.05%
-9.45
Total Other Finance Cost
—
—
—
—
Line Item Trend 2023-12-31 2022-12-31 2021-12-31
Total Assets
12.17
-15.83%
14.46
—
Current Assets
11.29
-15.59%
13.37
—
Cash Cash Equivalents And Short Term Investments
10.69
-16.79%
12.85
—
Cash And Cash Equivalents
2.40
-16.06%
2.86
—
Cash Financial
—
2.86
-61.77%
7.48
Other Short Term Investments
8.29
-17.00%
9.99
—
Prepaid Assets
0.56
+8.10%
0.52
—
Current Deferred Assets
0.03
0.00
0.00
Total Non Current Assets
0.88
-18.81%
1.09
—
Goodwill And Other Intangible Assets
0.58
-17.21%
0.70
—
Other Intangible Assets
0.58
-17.21%
0.70
—
Non Current Prepaid Assets
0.30
-21.75%
0.38
—
Other Non Current Assets
—
—
0.05
Total Liabilities Net Minority Interest
6.51
-7.74%
7.05
—
Current Liabilities
3.58
+1.53%
3.53
—
Payables And Accrued Expenses
3.58
+1.53%
3.53
—
Payables
1.22
-10.60%
1.37
—
Accounts Payable
0.53
-13.06%
0.61
—
Current Accrued Expenses
2.36
+9.18%
2.16
—
Pensionand Other Post Retirement Benefit Plans Current
—
—
—
Total Tax Payable
0.09
-41.11%
0.16
—
Other Current Liabilities
—
—
0.37
Total Non Current Liabilities Net Minority Interest
2.92
-17.03%
3.52
—
Tradeand Other Payables Non Current
0.00
0.00
—
Stockholders Equity
5.66
-23.53%
7.41
—
Common Stock Equity
5.66
-23.53%
7.41
—
Capital Stock
0.00
0.00
—
Common Stock
0.00
0.00
—
Share Issued
0.99
+144.43%
0.40
—
Ordinary Shares Number
0.99
+144.46%
0.40
—
Treasury Shares Number
0.00
-100.00%
0.00
+0.00%
0.00
Additional Paid In Capital
51.87
+8.38%
47.86
—
Retained Earnings
-46.20
-23.15%
-37.52
—
Gains Losses Not Affecting Retained Earnings
—
—
—
Treasury Stock
0.00
-100.00%
2.93
+0.00%
2.93
Other Equity Adjustments
—
—
—
Total Equity Gross Minority Interest
5.66
-23.53%
7.41
—
Total Capitalization
5.66
-23.53%
7.41
—
Working Capital
7.70
-21.72%
9.84
—
Invested Capital
5.66
-23.53%
7.41
—
Net Tangible Assets
5.08
-24.19%
6.70
—
Tangible Book Value
5.08
-24.19%
6.70
—
Dueto Related Parties Current
0.60
+0.00%
0.60
—
Dueto Related Parties Non Current
2.92
-17.03%
3.52
—
Interest Payable
1.15
+0.00%
1.15
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-13.54
-72.34%
-7.86
+0.09%
-7.86
+7.27%
-8.48
Cash Flow From Continuing Operating Activities
-13.54
-72.34%
-7.86
+0.09%
-7.86
+7.27%
-8.48
Net Income From Continuing Operations
-15.80
-76.34%
-8.96
-3.18%
-8.69
+7.41%
-9.38
Depreciation Amortization Depletion
0.10
+0.00%
0.10
-3.57%
0.10
-0.32%
0.10
Amortization Cash Flow
0.10
+0.00%
0.10
-3.57%
0.10
-0.32%
0.10
Depreciation And Amortization
0.10
+0.00%
0.10
-3.57%
0.10
-0.32%
0.10
Amortization Of Intangibles
0.10
+0.00%
0.10
-3.57%
0.10
-0.32%
0.10
Other Non Cash Items
—
—
—
0.71
Stock Based Compensation
1.15
-8.87%
1.26
+15.01%
1.09
+43.26%
0.76
Asset Impairment Charge
—
0.00
-100.00%
0.02
0.00
Operating Gains Losses
—
—
—
-0.49
Gain Loss On Investment Securities
—
—
—
-0.08
Unrealized Gain Loss On Investment Securities
-0.22
+14.20%
-0.25
+48.56%
-0.49
-421.52%
-0.09
Change In Working Capital
1.23
+57764.01%
-0.00
-102.24%
0.10
+201.16%
-0.09
Change In Prepaid Assets
-0.09
+66.61%
-0.28
-769.73%
0.04
-66.37%
0.12
Change In Payables And Accrued Expense
1.33
+380.20%
0.28
+411.75%
0.05
+124.76%
-0.22
Change In Accrued Expense
—
—
—
—
Change In Payable
1.33
+380.20%
0.28
+411.75%
0.05
+124.76%
-0.22
Change In Account Payable
1.33
+380.20%
0.28
+411.75%
0.05
+124.76%
-0.22
Investing Cash Flow
-4.28
-126.54%
-1.89
-186.29%
2.19
+121.56%
-10.15
Cash Flow From Continuing Investing Activities
-4.28
-126.54%
-1.89
-186.29%
2.19
+121.56%
-10.15
Capital Expenditure
—
—
—
-0.25
Net Investment Purchase And Sale
-4.28
-126.54%
-1.89
-186.29%
2.19
+122.11%
-9.90
Purchase Of Investment
-12.26
+28.92%
-17.25
+4.62%
-18.09
-82.75%
-9.90
Sale Of Investment
7.99
-48.03%
15.37
-24.23%
20.28
0.00
Net Intangibles Purchase And Sale
—
—
0.00
+100.00%
-0.25
Purchase Of Intangibles
—
—
0.00
+100.00%
-0.25
Financing Cash Flow
18.01
+64.25%
10.97
+110.24%
5.22
-62.76%
14.01
Cash Flow From Continuing Financing Activities
18.01
+64.25%
10.97
+110.24%
5.22
-62.76%
14.01
Net Issuance Payments Of Debt
—
—
0.00
+100.00%
-0.31
Issuance Of Debt
—
—
—
0.00
Repayment Of Debt
—
—
0.00
+100.00%
-0.31
Long Term Debt Issuance
—
—
—
—
Net Long Term Debt Issuance
—
—
—
—
Short Term Debt Issuance
—
—
—
0.00
Short Term Debt Payments
—
—
0.00
+100.00%
-0.31
Net Short Term Debt Issuance
—
—
0.00
+100.00%
-0.31
Net Other Financing Charges
18.01
+64.25%
10.97
+110.24%
5.22
-63.57%
14.32
Changes In Cash
0.20
-84.01%
1.22
+366.01%
-0.46
+90.06%
-4.62
Effect Of Exchange Rate Changes
-0.00
0.00
—
—
Beginning Cash Position
3.62
+50.90%
2.40
-16.06%
2.86
-61.77%
7.48
End Cash Position
3.82
+5.37%
3.62
+50.90%
2.40
-16.06%
2.86
Free Cash Flow
-13.54
-72.34%
-7.86
+0.09%
-7.86
+9.92%
-8.73
Interest Paid Supplemental Data
—
—
—
0.00
Change In Interest Payable
—
—
—
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category